RBC Capital cuts Regeneron stock rating, slashes target to $662

RBC Capital downgraded Regeneron (REGN) from Outperform to Sector Perform, significantly lowering the price target to $662 from $943 following disappointing clinical trial results for itepekimab; the drug failed to meet expectations despite one study meeting its primary endpoint. While Regeneron's long-term R&D and financial health remain promising with potential growth drivers like dupilumab and a low P/E ratio, near-term outperformance hinges on pipeline breakthroughs, dupilumab growth, or a major business development. The stock may continue to trade at a discount due to headwinds facing Eylea and uncertainties surrounding dupilumab's exclusivity.

Analysis

Regeneron Pharmaceuticals (NASDAQ:REGN) faces heightened scrutiny following RBC Capital Markets' downgrade from Outperform to Sector Perform, accompanied by a significant price target reduction to $662.00 from $943.00. This revision is primarily attributed to disappointing clinical trial results for its COPD drug candidate, itepekimab, which failed to consistently meet expectations across its Phase 3 studies; the AERIFY-1 study met its primary endpoint, but AERIFY-2 did not. The stock has reflected this pessimism, declining nearly 15% year-to-date to a trading price of $490.99. Despite these setbacks, Regeneron's underlying financial health is robust, as indicated by InvestingPro data showing a 'GREAT' overall score, a balance sheet with more cash than debt, and an attractive P/E ratio of 11.7x. Analyst Brian Abrahams from RBC acknowledges the company's strong long-term R&D capabilities and suggests the shares may be fundamentally undervalued, with potential for recovery aided by share buybacks and underappreciated assets like dupilumab, its broader pipeline, and repayments from its Sanofi collaboration. However, significant near-term stock appreciation is seen as dependent on a major pipeline breakthrough to replace itepekimab's multi-billion-dollar potential, accelerated growth or lifecycle clarity for dupilumab, or a impactful external business development. Persistent headwinds for Eylea and uncertainties around dupilumab's loss of exclusivity contribute to a cautious immediate outlook, potentially keeping the stock trading at a discount, even though InvestingPro’s Fair Value analysis suggests undervaluation. Other analysts offer mixed perspectives: Guggenheim and BMO Capital Markets maintain Buy/Outperform ratings with price targets of $810 and $800 respectively, anticipating a complex regulatory path, while Baird holds a Neutral rating ($587 target) due to trial inconsistencies, and Oppenheimer, despite an Outperform rating ($900 target), notes the unexpected AERIFY-2 failure and potential need for further trials. This divergence underscores the current uncertainty surrounding itepekimab's future and its impact on Regeneron's market strategy.

Key Decisions for Investors

• Investors should acknowledge the increased near-term risk profile for Regeneron due to the itepekimab trial setback and ongoing headwinds for key products like Eylea and dupilumab, which may continue to pressure the stock.
• Consider the potential for long-term value given Regeneron's strong financial fundamentals, including a low P/E ratio, more cash than debt, and an InvestingPro Fair Value assessment suggesting undervaluation, alongside existing growth drivers such as dupilumab.
• Closely monitor upcoming catalysts, including further pipeline developments, dupilumab's growth trajectory and lifecycle management strategies, potential share buyback activity, and any significant external business development initiatives.
• Evaluate the mixed Wall Street sentiment as indicative of a balanced risk-reward scenario, where downside from current disappointments is weighed against the company's established R&D capabilities and potential for recovery.